Quantum Pharmaceutical is the leading manufacturer and supplier of unlicensed medicines and special obtains. With a current portfolio of over 30,000 products, and 7 years manufacturing experience, we provide the widest range of unlicensed medicines and special obtain lines in the UK, making us the only true ‘one-stop-shop’ in the Specials industry.

In addition to our extensive product range, we also offer unrivalled turnaround times. Our 8am to 10pm opening hours enable us to process manufactured lines up until 6pm and stocked lines up until 9pm for delivery next day by noon. We are able to accept orders either by phone, fax, e-mail or via our online ordering portal. This flexible approach allows our customers to place their orders using their preferred method at a time convenient to them.

Our primary focus is quality and consistency and we are continuously expanding our product portfolio in order to satisfy individual patient needs and our innovations in product development and service delivery allow us to lead customer expectations in this crucial area. We have a combined quality assurance team of 34 people, 21 of whom are pharmacists on hand to assist customers with technical support and advice.


Quantum Pharma Plc

First Day of Dealings on AIM - 11 December 2014



http://www.quantumpharma.co.uk/

Half year results

Mucodis� Medical Device Launch
RNS
RNS Number : 6148E
Quantum Pharma PLC
05 November 2015







Press Release
5 November 2015




Quantum Pharma Plc



("Quantum" or the "Group")



Mucodis® Medical Device Launch



Quantum Pharma Plc (AIM:QP.), the growing, service-led niche pharmaceutical manufacturer, developer and supplier to the health and care sectors, is pleased to announce that Colonis, part of its newly formed Niche Pharmaceuticals division, has launched its in-licensed range of patented medical devices to treat some of the side effects of cancer treatment in patients.



This range initially comprises up to seven products that are used to treat the side effects of chemotherapy and radiotherapy, specifically the inflammation of different mucosal membranes of the body, including that of the mouth and rectum. The range will be marketed and sold in the UK under the Mucodis® brand name.



Some 330,000 patients in the UK are diagnosed with cancer every year and most suffer painful or unpleasant side effects as they progress with treatment. The Mucodis® range provides the NHS with prescribable products for a number of associated conditions, including mucositis, dermatitis and proctitis. Colonis has been granted an exclusive distribution licence for these products for five years, with an option to extend beyond this initial period.



The first product in the range, Mucodis® Oromucosal Spray for the treatment of oral mucositis, a painful inflammation of the mouth that can follow certain typical cancer treatments, is launched today, with a preventative mouthwash expected to follow later this financial year. Of the 330,000 new instances of cancer in the UK every year, approximately 132,000 (40%) patients will typically develop some degree of oral mucositis as a result of standard treatment therapies. This figure is higher in paediatric oncology patients (90% of patients), as well as in patients receiving irradiation for neck and head cancers (97% of patients). Previously there have been limited options to manage this side effect. It is anticipated that additional Mucodis® products will be launched in the next financial year.



To support the launch of this range of products, Quantum has a specific therapeutic sales team in place, which has been active amongst oncology specialists, nurses and pharmacists establishing demand for these products. As a result of this, the entire first manufacturing batch of Mucodis® Oromucosal Spray has been bought by the pharmaceutical wholesale chain to ensure access for these prescribers.


Andy Scaife, CEO of Quantum Pharma, commented: "We are excited to be making available the first product in the Mucodis® range. This range has the potential to make a difference for patients living with the side effects of cancer treatment commonly triggered by radiotherapy and chemotherapy. The launch of Mucodis® and the developments within this team mark a promising new chapter for both Niche Pharmaceuticals and the Group's expansion into regulated products, with a number of further medical device and licensed product launches anticipated during the current financial year."









- Ends -

MEET THE TECH SUPERSTARS OF TOMORROW

A 12-month share price performance of the companies that presented at the Innovators & Investors Forum last year included:

Elecosoft +42%
Idox +22%
Instem +34%
KBC Advanced +45%
XL Media +41%

The Innovators & Investors Forum, organised in partnership with Cenkos Securities and SHARES, is in its 4th year and is the UK's only technology investment show.

REGISTER NOW

Thousands of investors have attended our previous shows, attendees will also benefit from:

Learning from industry experts and influencers about the markets, the technology sector and individual companies
Find out from fund managers how they view the future in 2016
Meet the directors of up to 30 listed technology focused companies
Listen to our expert team of SHARES journalists

The event is supported with an extensive conference program
Keynote Speakers:

Daniel Coatsworth, Editor - Shares
Mark Dunne, Growth Companies Reporter - SHARES
Steven Frazer, Online Editor - SHARES
Russ Mould, Investment Director - AJ Bell
Richard Penny, Senior Fund Manager - Legal & General UK Alpha Trust
Simon Strong, Head of Research, Growth Companies - Cenkos Securities
Gervais Williams, MD - Miton Group

Further speakers to be announced soon.

Meet the teams and talk directly to CEOs and Directors from:


Advanced Oncotherapy
Abzena
Advanced Oncotherapy
ANGLE
Brady
CML Microsystems
Cyan
Eckoh
eg solutions
Flowgroup
Ilika
Instem
Kromek
Lombard Risk
Mirada
Plastics Capital
Quantum Pharma
Rosslyn Data Technologies
Selftrade
SHARES
TyraTech

Further companies to be announced soon.




Date: 2nd February 2016

Venue: Business Design Centre, London


Event timings

Registration: from 09:00
Conference: 09:45 - 17:00
Exhibition: 09:00 - 18:00



REGISTER NOW